A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 1, 2016, Pages 169-178

  Brunner, Patrick M ^a   Khattri, Saakshi ^a,b   Garcet, Sandra ^a   Finney, Robert ^c   Oliva, Margeaux ^a,b   Dutt, Riana ^a,b   Fuentes Duculan, Judilyn ^a   Zheng, Xiuzhong ^a   Li, Xuan ^a   Bonifacio, Kathleen M ^a   Kunjravia, Norma ^a   Coats, Israel ^a   Cueto, Inna ^a   Gilleaudeau, Patricia ^a   Sullivan Whalen, Mary ^a   Suárez Fariñas, Mayte ^a,b   Krueger, James G ^a   Guttman Yassky, Emma ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Atopic dermatitis; epidermal; immune; topical glucocorticosteroids; triamcinolone acetonide

Indexed keywords

CALGRANULIN A; CHEMOKINE CCL18; CXCL9 CHEMOKINE; CYTOKERATIN 16; EOTAXIN 3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23P19; INTERLEUKIN 34; LORICRIN; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE ELASTASE; PEPTIDASE INHIBITOR 3; PROTEIN S 100; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; STEROID;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DOWN REGULATION; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; PRIORITY JOURNAL; SKIN BIOPSY; STEROID THERAPY; TREATMENT RESPONSE; BIOPSY; CLUSTER ANALYSIS; DERMATITIS, ATOPIC; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SKIN; T LYMPHOCYTE SUBPOPULATION; TIME FACTOR; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOPSY; CLUSTER ANALYSIS; DERMATITIS, ATOPIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN; STEROIDS; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84961150839     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.12.1323     Document Type: Article

References (42)

1. 1 Leung, D.Y., Guttman-Yassky, E., Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 134 (2014), 769–779.
2. 2 Brazzini, B., Pimpinelli, N., New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 3 (2002), 47–58.
3. 3 Suarez-Farinas, M., Ungar, B., Correa da Rosa, J., Ewald, D.A., Rozenblit, M., Gonzalez, J., et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 135 (2015), 1218–1227.
4. 4 Czarnowicki, T., Krueger, J.G., Guttman-Yassky, E., Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract 2 (2014), 371–379.
5. 5 Czarnowicki, T., Gonzalez, J., Shemer, A., Malajian, D., Xu, H., Zheng, X., et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol 136 (2015), 104–115.e7.
6. 6 Czarnowicki, T., Esaki, H., Gonzalez, J., Malajian, D., Shemer, A., Noda, S., et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol 136 (2015), 941–951.e3.
7. 7 Czarnowicki, T., Gonzalez, J., Bonifacio, K.M., Shemer, A., Xiangyu, P., Kunjravia, N., et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol 137 (2016), 118–129.e5.
8. 8 Khattri, S., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., Finney, R., et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 133 (2014), 1626–1634.
9. 9 Hamilton, J.D., Suarez-Farinas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134 (2014), 1293–1300.
10. 10 Beck, L.A., Thaci, D., Hamilton, J.D., Graham, N.M., Bieber, T., Rocklin, R., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371 (2014), 130–139.
11. 11 Coutinho, A.E., Chapman, K.E., The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335 (2011), 2–13.
12. 12 Jensen, J.M., Scherer, A., Wanke, C., Bräutigam, M., Bongiovanni, S., Letzkus, M., et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 67 (2012), 413–423.
13. 13 Barnes, P.J., Corticosteroid effects on cell signalling. Eur Respir J 27 (2006), 413–426.
14. 14 Jensen, J.M., Weppner, M., Dahnhardt-Pfeiffer, S., Neumann, C., Bräutigam, M., Schwarz, T., et al. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial. Acta Derm Venereol 93 (2013), 515–519.
15. 15 Hengge, U.R., Ruzicka, T., Schwartz, R.A., Cork, M.J., Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54 (2006), 1–15.
16. 16 Mohan, G.C., Lio, P.A., Comparison of dermatology and allergy guidelines for atopic dermatitis management. JAMA Dermatol 151 (2015), 1009–1013.
17. 17 Eichenfield, L.F., Tom, W.L., Berger, T.G., Krol, A., Paller, A.S., Schwarzenberger, K., et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71 (2014), 116–132.
18. 18 Sidbury, R., Tom, W.L., Bergman, J.N., Cooper, K.D., Silverman, R.A., Berger, T.G., et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol 71 (2014), 1218–1233.
19. 19 Norris, D.A., Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 53 (2005), S17–S25.
20. 20 Mizuno, K., Morizane, S., Takiguchi, T., Iwatsuki, K., Dexamethasone but not tacrolimus suppresses TNF-alpha-induced thymic stromal lymphopoietin expression in lesional keratinocytes of atopic dermatitis model. J Dermatol Sci 80 (2015), 45–53.
21. 21 Hoetzenecker, W., Meingassner, J.G., Ecker, R., Stingl, G., Stuetz, A., Elbe-Burger, A., Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 122 (2004), 673–684.
22. 22 Harcharik, S., Emer, J., Steroid-sparing properties of emollients in dermatology. Skin Therapy Lett 19 (2014), 5–10.
23. 23 Kabashima-Kubo, R., Nakamura, M., Sakabe, J., Sugita, K., Hino, R., Mori, T., et al. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. J Dermatol Sci 67 (2012), 37–43.
24. 24 Noda, S., Suarez-Farinas, M., Ungar, B., Kim, S.J., de Guzman Strong, C., Xu, H., et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased T17 polarization. J Allergy Clin Immunol 136 (2015), 1254–1264.
25. 25 Tintle, S., Shemer, A., Suarez-Farinas, M., Fujita, H., Gilleaudeau, P., Sullivan-Whalen, M., et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 128 (2011), 583–593 e1-4.
26. 26 Suarez-Farinas, M., Tintle, S.J., Shemer, A., Chiricozzi, A., Nograles, K., Cardinale, I., et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 127 (2011), 954–964 e1-4.
27. 27 Suarez-Farinas, M., Pellegrino, M., Wittkowski, K.M., Magnasco, M.O., Harshlight: a “corrective make-up” program for microarray chips. BMC Bioinformatics, 6, 2005, 294.
28. 28 Wu, Z., Irizarry, R., Gentleman, R., Martinez-Murillo, F., Spencer, F., A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99 (2004), 909–917.
29. 29 Freedberg, I.M., Tomic-Canic, M., Komine, M., Blumenberg, M., Keratins and the keratinocyte activation cycle. J Invest Dermatol 116 (2001), 633–640.
30. 30 Mansouri, Y., Guttman-Yassky, E., Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med 4 (2015), 858–873.
31. 31 Esaki, H., Ewald, D.A., Ungar, B., Rozenblit, M., Zheng, X., Xu, H., et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol 135 (2015), 153–163.
32. 32 Wollenberg, A., Mommaas, M., Oppel, T., Schottdorf, E.M., Gunther, S., Moderer, M., Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. J Invest Dermatol 118 (2002), 327–334.
33. 33 Guttman-Yassky, E., Lowes, M.A., Fuentes-Duculan, J., Whynot, J., Novitskaya, I., Cardinale, I., et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 119 (2007), 1210–1217.
34. 34 Suarez-Farinas, M., Lowes, M.A., Zaba, L.C., Krueger, J.G., Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One, 5, 2010, e10247.
35. 35 Jensen, J.M., Pfeiffer, S., Witt, M., Bräutigam, M., Neumann, C., Weichenthal, M., et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 123 (2009), 1124–1133.
36. 36 Noda, S., Krueger, J.G., Guttman-Yassky, E., The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 135 (2015), 324–336.
37. 37 Thaci, D., Simpson, E.L., Beck, L.A., Bieber, T., Blauvelt, A., Papp, K., et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387 (2016), 40–52.
38. 38 Singh, G., Singh, P.K., Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int J Dermatol 25 (1986), 324–326.
39. 39 Suarez-Farinas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol 132 (2013), 361–370.
40. 40 Gittler, J.K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K.J., Wang, C.Q., et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130 (2012), 1344–1354.
41. 41 Correa da Rosa, J., Malajian, D., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., et al. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. J Allergy Clin Immunol 135 (2015), 712–720.
42. 42 Leung, D.Y., Gao, P.S., Grigoryev, D.N., Rafaels, N.M., Streib, J.E., Howell, M.D., et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-gamma response. J Allergy Clin Immunol 127 (2011), 965–973 e1-5.